NDAORALCAPSULE
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
ACTICLATE CAP (doxycycline hyclate) by Molecular Devices is 12. First approved in 2016.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ACTICLATE CAP is a doxycycline hyclate capsule, a tetracycline-class antimicrobial that inhibits bacterial protein synthesis. It is an oral antibiotic used to treat a broad spectrum of bacterial infections across multiple therapeutic areas. The drug is absorbed rapidly with peak plasma levels at 3 hours and demonstrates a serum half-life of 18–22 hours independent of renal function.
Peak
Product is at peak lifecycle with moderate competitive pressure (30), indicating a mature market with stable but non-growth commercial operations and a focused team.
Mechanism of Action
12.1 Mechanism of Action Doxycycline is a tetracycline-class antimicrobial drug [see ] . 12.3 Pharmacokinetics Absorption Doxycycline hyclate tablets: Following administration of a single 300 mg dose to adult volunteers, average peak plasma doxycycline levels were 3.0 mcg per mL at 3 hours,…
Worked on ACTICLATE CAP at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.